Call 13 der Innovative Medicines Initiative (IMI2) wird voraussichtlich mit 16 Topics öffnen. Die Einreichfristen für Kurzanträge (1. Stufe) werden voraussichtlich am 28. Februar 2018 enden, jene für Vollanträge (2. Stufe) am 6. September 2018. Für diesen Call sollen 124,5 Mio EUR von IMI2 zur Verfügung gestellt werden, und 113,5 Mio EUR in Form von in-kind Leistungen von EFPIA (European Federation of Pharmaceutical Industries and Associations).


Alle außer Topic 5 werden als RIAs (Research and Innovation Actions) ausgeschrieben, während Topic 5 eine CSA (Coordination and Support Action) sein wird.  

Topic 1:   Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches

Topic 2:   Genome-Environment Interaction in Inflammatory Skin Disease

Topic 3:   The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use

Topic 4:   Mitochondrial Dysfunction in Neurodegeneration

Topic 5:   Support and coordination action for the projects of the Neurodegeneration area of the Innovative Medicines Initiative

Topic 6:   A sustainable European induced pluripotent stem cell platform

Topic 7:   Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice (DIAMOND)

Topic 8:   Human Tumour Microenvironment Immunoprofiling

Topic 9:   ConcePTION – Continuum of Evidence from Pregnancy Exposures, Reproductive Toxicology & Breastfeeding to Improve Outcomes Now

Topic 10: Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system

Topic 11: Translational Safety Biomarker Pipeline (TransBioLine): Enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease

Topic 12: Federated and privacy-preserving machine learning in support of drug discovery

Topic 13: Pilot Programme on a Clinical Compound for Repurposing- Cardiovascular diseases and diabetes

Topic 14: Pilot Programme on a Clinical Compound for Repurposing - Respiratory diseases

Topic 15: Pilot Programme on a Clinical Compound for Repurposing - Neurodegenerative diseases

Topic 16: Pilot Programme on a Clinical Compound for Repurposing - Rare/orphan diseases


Die vorläufigen Topic Beschreibungen finden Sie unter